Glioma Glioblastoma Multiforme Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting glioma glioblastoma multiforme clinical trials across 5 countries. Studies span Phase 1, Phase 2, Not Applicable. Top locations include Changsha, Hunan, China, Chicago, Illinois, United States, Columbus, Ohio, United States. Updated daily from ClinicalTrials.gov.


Glioma Glioblastoma Multiforme Trials at a Glance

7 actively recruiting trials for glioma glioblastoma multiforme are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Changsha, Chicago, and Columbus. Lead sponsors running glioma glioblastoma multiforme studies include Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Marzieh Ebrahimi, and Abramson Cancer Center at Penn Medicine.

Browse glioma glioblastoma multiforme trials by phase

About Glioma Glioblastoma Multiforme Clinical Trials

Looking for clinical trials for Glioma Glioblastoma Multiforme? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glioma Glioblastoma Multiforme trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glioma Glioblastoma Multiforme clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

GliomasGlioma Glioblastoma MultiformeGliomas Harboring IDH1 and/or IDH2 Mutations+3 more
Xiangya Hospital of Central South University500 enrolled1 locationNCT07608003
Recruiting

PET-Guided Resection in High-Grade Gliomas

Positron-Emission Tomography(PET)Glioma Glioblastoma MultiformeGlioma, High Grade+1 more
Universita degli Studi di Genova100 enrolled2 locationsNCT07567196
Recruiting
Phase 1Phase 2

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Lung CancerNon-small Cell Lung CancerSolid Tumor+4 more
Tango Therapeutics, Inc.191 enrolled15 locationsNCT06810544
Recruiting
Not Applicable

WBSI Guided Personalized Delivery of TTFields

GBMTumor, BrainGlioma Glioblastoma Multiforme
Abramson Cancer Center at Penn Medicine155 enrolled2 locationsNCT05086497
Recruiting
Phase 2

Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas

Glioma Glioblastoma MultiformeHigh Grade Glioma (III or IV)
Marzieh Ebrahimi40 enrolled1 locationNCT06687681
Recruiting
Phase 1

Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma

Glioma Glioblastoma Multiforme
Theragnostics Ltd67 enrolled2 locationsNCT06650605
Recruiting

Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness

GlioblastomaGliomaGlioma Glioblastoma Multiforme
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico400 enrolled1 locationNCT06348693